Feature | August 15, 2012| Dave Fornell

TAVR, EVAR Vascular Closure Device May Eliminate Need for Surgical Cut-Down

Transapical access closure

Due to the increasing number of transcatheter aortic valve replacements (TAVR) and endovascular aneurysm repair (EVAR), a new startup company has developed a transfemoral combined access and closure system to accomodate these larger sized percutaneous devices and arteriotomies. Introduced in sessions at the 2012 American College of Cardiology (ACC) and EuroPCR, the VasoStitch system is designed to reduce procedural complexity and eliminate the need for open surgical cut-downs and surgical closure of the vessel.

The company is also developing a similar transapical TAVR access and closure device to eliminate the need to sew surgical purse-string sutures at the apex of the heart prior to introducer placement. This may significanty shorten and simplify transapical valve replacement procedures.

The system uses a helical, corkscrew-shaped, barbed suturing needle that is advanced through the vessel wall and surrounding tissue prior to vessel access. Access is accomplished though the center of the suture needle coil. When the procedure is complete, a suture tail is pulled to close the vessel and activate a bioresorbable suture lock.

“At the present time, surgical means of arterial or cardiac access-and-closure for large-diameter, catheter-based interventions such as TAVI adds about 60 minutes to an already lengthy and elaborate procedure. As a result, a device that can duplicate the current ‘gold standard’ of surgical access and repair — but in a quicker and simpler, nonsurgical procedure — will surely stimulate the adoption of large-diameter cardiovascular and endovascular therapies, as well as improve the efficiency of patient management,” said David W. J. Smith, president and CEO of Danville, Calif.-based VasoStitch. “We are moving quickly toward our first-in-human milestone.”

For more information: www.vasostitch.com

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology| May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...
New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair
News | Endovascular Aortic Repair| May 23, 2017
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and...
Nearly One-Quarter of Patients Say Mechanical Heart Valve Disturbs Sleep
News | Heart Valve Technology| May 19, 2017
Nearly one-quarter of patients with a mechanical heart valve say it disturbs their sleep, according to research...
Analysis Looks at Role Type of Valve Plays in Patient Outcomes Post-TAVR
News | Heart Valve Technology| May 15, 2017
For patients who undergo transcatheter aortic valve replacement (TAVR), their risk factors, not the type of valve used...
Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve
News | Heart Valve Technology| May 03, 2017
The Baylor Jack and Jane Hamilton Heart and Vascular Hospital (BHVH) transcatheter aortic valve replacement (TAVR) team...
Alabama Medical Center First in Southeast to Offer CoreValve Evolut Pro TAVR Device
News | Heart Valve Technology| April 20, 2017
The Structural Heart Program at Princeton Baptist Medical Center, (Birmingham, Ala.) recently became the first center...
Updated AATS Guidelines Help Cardiovascular Surgeons Navigate Challenges of Managing Ischemic Mitral Regurgitation
News | Heart Valve Technology| April 20, 2017
April 20, 2017 — Mitral regurgitation can occur in up to 50 percent of patients with ischemic heart disease and even
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Boston Scientific is buying TAVI valve maker Symetis, which has European approval for its Acurate Neo valve

The Symetis Acurate Neo TAVI valve.

News | Heart Valve Technology| April 11, 2017
April 10, 2017 — Boston Scientific recently announced a $435 million cash deal to acquire Symetis SA, a privately-hel
News | Stent Grafts| April 06, 2017
Endologix Inc. announced that the first patients were treated in the Expanding Patient Applicability with Polymer...
Overlay Init